

# SECURITIES AND EXCHANGE COMMISSION

## FORM SC 13G

Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions

Filing Date: **1994-01-12**  
SEC Accession No. **0000315066-94-000028**

([HTML Version](#) on [secdatabase.com](http://secdatabase.com))

### SUBJECT COMPANY

#### **CREATIVE BIOMOLECULES INCORPORATED**

CIK: **857121** | IRS No.: **942786743** | State of Incorpor.: **DE** | Fiscal Year End: **0930**  
Type: **SC 13G** | Act: **34** | File No.: **005-42517** | Film No.: **94501185**  
SIC: **2836** Biological products, (no diagnostic substances)

Business Address  
45 S ST  
HOPKINTON MA 01748  
5084359001

### FILED BY

#### **FMR CORP**

CIK: **315066** | State of Incorpor.: **MA** | Fiscal Year End: **1231**  
Type: **SC 13G**

Business Address  
82 DEVONSHIRE ST  
BOSTON MA 02109  
6175706339

SCHEDULE 13G

Amendment No.

Creative Biomolecules Incorporated

common stock

Cusip # 225270107

Filing Fee: Yes

Cusip # 225270107

Item 1: Reporting Person - FMR Corp. - (Tax ID: 04-2507163)

Item 4: Commonwealth of Massachusetts

Item 5: 55,900

Item 6: None

Item 7: 1,696,600

Item 8: None

Item 9: 1,696,600

Item 11: 10.83%

Item 12: HC

Cusip # 225270107

Item 1: Reporting Person - Edward C. Johnson 3d - (Tax ID: ###-##-####)

Item 4: United States of America

Item 5: None

Item 6: None

Item 7: 1,696,600

Item 8: None

Item 9: 1,696,600

Item 11: 10.83%

Item 12: IN

SCHEDULE 13G - TO BE INCLUDED IN STATEMENTS

FILED PURSUANT TO RULE 13d-1(b) or 13d-2(b)

Item 1(a). Name of Issuer:

Creative Biomolecules Incorporated

Item 1(b). Name of Issuer's Principal Executive Offices:

35 South Street  
Hopkinton, MA 01748

Item 2(a). Name of Person Filing:

FMR Corp.

Item 2(b). Address or Principal Business Office or, if None, Residence:

82 Devonshire Street, Boston, Massachusetts 02109

Item 2(c). Citizenship:

Not applicable

Item 2(d). Title of Class of Securities:

common stock

Item 2(e). CUSIP Number:

225270107

Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) and the person filing, FMR Corp., is a parent holding company in accordance with Section 240.13d-1(b)(ii)(G). (Note: See Item 7).

Item 4. Ownership

(a) Amount Beneficially Owned: 1,696,600

(b) Percent of Class: 10.83%

(c) Number of shares as to which such person has:

(i) sole power to vote or to direct the vote: 55,900

(ii) shared power to vote or to direct the vote: None

(iii) sole power to dispose or to direct the disposition of:

1,696,600

(iv) shared power to dispose or to direct the disposition

of: None

Item 5. Ownership of Five Percent or Less of a Class.

Not applicable.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the common stock of Creative Biomolecules Incorporated. No one person's interest in the common stock of Creative Biomolecules Incorporated is more than five

percent of the total outstanding common stock.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

See attached Exhibit(s) A and B.

Item 8. Identification and Classification of Members of the Group.

Not applicable, see attached Exhibit A.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purpose or effect.

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

January 10, 1994

Date

Signature

Arthur S. Loring, Vice President

Name/Title

SCHEDULE 13G - TO BE INCLUDED IN STATEMENTS  
FILED PURSUANT TO RULE 13d-1(b) or 13d-2(b)

Pursuant to the instructions in Item 7 of Schedule 13G, Fidelity Management & Research Company ("Fidelity"), 82 Devonshire Street, Boston, Massachusetts 02109, a wholly-owned subsidiary of FMR Corp. and an investment adviser registered under Section 203 of the Investment Advisers Act of 1940, is the beneficial owner of 1,572,800 shares or 10.04% of the common stock outstanding of Creative Biomolecules Incorporated ("the Company") as a result of acting as investment adviser to several investment companies registered under Section 8 of the Investment Company Act of 1940.

Edward C. Johnson 3d, FMR Corp., through its control of Fidelity, and the Funds each has sole power to dispose of the 1,572,800 shares owned by the Funds.

Neither FMR Corp. nor Edward C. Johnson 3d, Chairman of FMR Corp., has the sole power to vote or direct the voting of the Shares owned directly by the Fidelity Funds, which power resides with the Funds' Boards of Trustees. Fidelity carries out the voting of the Shares under written guidelines established by the Funds' Boards of Trustees.

Fidelity Management Trust Company, 82 Devonshire Street, Boston, Massachusetts 02109, a wholly-owned subsidiary of FMR Corp. and a bank as defined in Section 3(a)(6) of the Securities Exchange Act of 1934, is the beneficial owner of 123,800 shares or 0.79% of the common stock outstanding of the company as a result of its serving as investment manager of the institutional account(s).

FMR Corp., through its control of Fidelity Management Trust Company, has sole dispositive power over 123,800 Shares and sole power to vote or to direct the voting of 55,900 shares, and no power to vote or to direct the voting of 67,900 Shares of common stock owned by the institutional account(s) as reported above.

Edward C. Johnson 3d owns 34.0% of the outstanding voting common stock of FMR Corp. Mr. Johnson 3d is Chairman of FMR Corp. Various Johnson family members and trusts for the benefit of Johnson family members own FMR Corp. voting common stock. These Johnson family members, through their ownership of voting common stock, form a controlling group with respect to FMR Corp.

SCHEDULE 13G - TO BE INCLUDED IN STATEMENTS  
FILED PURSUANT TO RULE 13d-1(b) or 13d-2(b)

RULE 13d-1(e) AGREEMENT

The undersigned persons, on January 10, 1994, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the common stock of Creative Biomolecules Incorporated at December 31, 1993.

FMR Corp.

By

Arthur S. Loring  
Vice President - Legal

By

Arthur S. Loring

Under Power of Attorney

dated 5/17/89

On File with Schedule 13G

for

Airborne Freight Corp.

9/10/91

Fidelity Management & Research Company

By

Arthur S. Loring

Sr. V.P. and General

Counsel